IA-2 autoantibody affinity in children at risk for type 1 diabetes

Clinical Immunology

Volumn 145, Issue 3, 2012, Pages 224-229

  Krause, Stephanie ^a   Chmiel, Ruth ^b   Bonifacio, Ezio ^c   Scholz, Marlon ^a   Powell, Michael ^d   Furmaniak, Jadwiga ^d   Rees Smith, Bernard ^d   Ziegler, Anette G ^a,b   Achenbach, Peter ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Forschergruppe Diabetes eV   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d RSR LTD   (United Kingdom)

Author keywords

Affinity; Diabetes risk; Epitopes; IA 2 autoantibodies; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; EPITOPE; HLA ANTIGEN CLASS 2; INSULINOMA ASSOCIATED PROTEIN 2; INSULINOMA ASSOCIATED PROTEIN 2BETA; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DOMAIN; SCHOOL CHILD;

ADOLESCENT; ANTIBODY AFFINITY; AUTOANTIBODIES; AUTOANTIGENS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; EPITOPES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISLETS OF LANGERHANS; MALE; PROSPECTIVE STUDIES; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; RISK FACTORS; YOUNG ADULT;

EID: 84867834141     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.09.010     Document Type: Article

References (30)

1. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
2. Achenbach P., Lampasona V., Landherr U., Koczwara K., Krause S., Grallert H., Winkler C., Pflueger M., Illig T., Bonifacio E., Ziegler A.G. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009, 52:1881-1888.
3. Yu L., Boulware D.C., Beam C.A., Hutton J.C., Wenzlau J.M., Greenbaum C.J., Bingley P.J., Krischer J.P., Sosenko J.M., Skyler J.S., Eisenbarth G.S., Mahon J.L. Type 1 Diabetes TrialNet Study Group, Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012, 35:1213-1218.
4. Long A.E., Gooneratne A.T., Rokni S., Williams A.J., Bingley P.J. The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort. J Clin Endocrinol Metab 2012, 97:632-637.
5. De Grijse J., Asanghanwa M., Nouthe B., Albrecher N., Goubert P., Vermeulen I., Van Der Meeren S., Decochez K., Weets I., Keymeulen B., Lampasona V., Wenzlau J., Hutton J.C., Pipeleers D., Gorus F.K., Belgian Diabetes R. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010, 53:517-524.
6. Orban T., Sosenko J.M., Cuthbertson D., Krischer J.P., Skyler J.S., Jackson R., Yu L., Palmer J.P., Schatz D., Eisenbarth G., Diabetes Prevention G. Diabetes Prevention Trial-Type 1 Study Group, Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009, 32:2269-2274.
7. Achenbach P., Warncke K., Reiter J., Naserke H.E., Williams A.J., Bingley P.J., Bonifacio E., Ziegler A.G. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004, 53:384-392.
8. Siljander H.T., Simell S., Hekkala A., Lahde J., Simell T., Vahasalo P., Veijola R., Ilonen J., Simell O., Knip M. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 2009, 58:2835-2842.
9. Achenbach P., Koczwara K., Knopff A., Naserke H., Ziegler A.G., Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004, 114:589-597.
10. Mayr A., Schlosser M., Grober N., Kenk H., Ziegler A.G., Bonifacio E., Achenbach P. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007, 56:1527-1533.
11. Ziegler A.G., Hummel M., Schenker M., Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
12. Kimpimaki T., Kulmala P., Savola K., Kupila A., Korhonen S., Simell T., Ilonen J., Simell O., Knip M. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2002, 87:4572-4579.
13. Colman P.G., Steele C., Couper J.J., Beresford S.J., Powell T., Kewming K., Pollard A., Gellert S., Tait B., Honeyman M., Harrison L.C. Islet autoimmunity in infants with a type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000, 43:203-209.
14. Yu L., Robles D.T., Abiru N., Kaur P., Rewers M., Kelemen K., Eisenbarth G.S. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 2000, 97:1701-1706.
15. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., Rewers M., Eisenbarth G.S., Jensen J., Davidson H.W., Hutton J.C. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104:17040-17045.
16. Sosenko J.M., Skyler J.S., Palmer J.P., Krischer J.P., Cuthbertson D., Yu L., Schatz D.A., Orban T., Eisenbarth G., Diabetes Prevention T.-T., Type G. 1 Diabetes TrialNet Study, A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 2011, 34:2435-2437.
17. Achenbach P., Bonifacio E., Williams A.J., Ziegler A.G., Gale E.A., Bingley P.J., Group E. Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia 2008, 51:488-492.
18. Christie M.R., Genovese S., Cassidy D., Bosi E., Brown T.J., Lai M., Bonifacio E., Bottazzo G.F. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994, 43:1254-1259.
19. Torn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J., Participating L. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
20. Schlosser M., Mueller P.W., Torn C., Bonifacio E., Bingley P.J., Participating L. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010, 53:2611-2620.
21. Lampasona V., Schlosser M., Mueller P.W., Williams A.J., Wenzlau J.M., Hutton J.C., Achenbach P. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011, 57:1693-1702.
22. Bonifacio E., Lampasona V., Bingley P.J. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998, 161:2648-2654.
23. Lampasona V., Belloni C., Piquer S., Bonicchio S., Furlan R., Bonifacio E. Radiobinding assay for detecting autoantibodies to single epitopes. J Immunol Methods 2008, 336:127-134.
24. M. Masuda, M. Powell, S. Chen, C. Beer, P. Fichna, B. Rees Smith, J. Furmaniak, Autoantibodies to IA-2 in insulin-dependent diabetes mellitus. Measurements with a new immunoprecipitation assay, Clinica chimica acta; international journal of clinical chemistry, 291 (2000) 53-66.
25. Walter M., Albert E., Conrad M., Keller E., Hummel M., Ferber K., Barratt B.J., Todd J.A., Ziegler A.G., Bonifacio E. IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity. Diabetologia 2003, 46:712-720.
26. Siljander H., Harkonen T., Hermann R., Simell S., Hekkala A., Salonsaari R.T., Simell T., Simell O., Ilonen J., Veijola R., Knip M. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009, 25:615-622.
27. Lampasona V., Bearzatto M., Genovese S., Bosi E., Ferrari M., Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 1996, 157:2707-2711.
28. Weenink S.M., Lo J., Stephenson C.R., McKinney P.A., Ananieva-Jordanova R., Rees Smith B., Furmaniak J., Tremble J.M., Bodansky H.J., Christie M.R. Autoantibodies and associated T-cell responses to determinants within the 831-860 region of the autoantigen IA-2 in Type 1 diabetes. J Autoimmun 2009, 33:147-154.
29. Hoppu S., Harkonen T., Ronkainen M.S., Simell S., Hekkala A., Toivonen A., Ilonen J., Simell O., Knip M. IA-2 antibody isotypes and epitope specificity during the prediabetic process in children with HLA-conferred susceptibility to type I diabetes. Clin Exp Immunol 2006, 144:59-66.
30. Kawasaki E., Sera Y., Abiru N., Yamauchi M., Ozaki M., Yamakawa K., Abe T., Uotani S., Yamasaki H., Yamaguchi Y., Eguchi K. Distinct IA-2 autoantibody epitope recognition between childhood-onset and adult-onset type 1 diabetes. Ann N Y Acad Sci 2002, 958:235-240.